<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38772678</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>20</Day></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Severe enterovirus infections in patients with immune-mediated inflammatory diseases receiving anti-CD20 monoclonal antibodies.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e004036</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2023-004036</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Patients with X linked agammaglobulinemia are susceptible to enterovirus (EV) infections. Similarly, severe EV infections have been described in patients with impaired B-cell response following treatment with anti-CD20 monoclonal antibodies (mAbs), mostly in those treated for haematological malignancies. We aimed to describe severe EV infections in patients receiving anti-CD20 mAbs for immune-mediated inflammatory diseases (IMIDs).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients were included following a screening of data collected through the routine surveillance of EV infections coordinated by the National Reference Center and a review of the literature. Additionally, neutralising antibodies were assessed in a patient with chronic EV-A71 meningoencephalitis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nine original and 17 previously published cases were retrieved. Meningoencephalitis (n=21/26, 81%) associated with EV-positive cerebrospinal fluid (n=20/22, 91%) was the most common manifestation. The mortality rate was high (27%). EV was the only causal agents in all reported cases. Patients received multiple anti-CD20 mAbs infusions (median 8 (5-10)), resulting in complete B-cell depletion and moderate hypogammaglobulinemia (median 4.9 g/L (4.3-6.7)), and had limited concomitant immunosuppressive treatments. Finally, in a patient with EV-A71 meningoencephalitis, a lack of B-cell response to EV was shown.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">EV infection should be evoked in patients with IMIDs presenting with atypical organ involvement, especially meningoencephalitis. Anti-CD20 mAbs may lead to impaired B-cell response against EV, although an underlying primary immunodeficiency should systematically be discussed.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martin de Frémont</LastName><ForeName>Grégoire</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3393-3969</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Université Paris Cité, Hôpital Cochin, Paris, France gregoire.martin-de-fremont@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chabrolles</LastName><ForeName>Hélène</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>3IHP-Infection Inflammation et Interaction Hôtes Pathogènes, Virology Department, National Reference Centre for Enteroviruses and Parechoviruses, Coordination Laboratory, CHU, Clermont-Ferrand, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LMGE UMR CNRS 6023, Team Epidemiology and Pathophysiology of Enterovirus Infection, Université Clermont Auvergne, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirand</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>3IHP-Infection Inflammation et Interaction Hôtes Pathogènes, Virology Department, National Reference Centre for Enteroviruses and Parechoviruses, Coordination Laboratory, CHU, Clermont-Ferrand, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LMGE UMR CNRS 6023, Team Epidemiology and Pathophysiology of Enterovirus Infection, Université Clermont Auvergne, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L'Honneur</LastName><ForeName>Anne Sophie</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Virology, Hôpital Cochin, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Cochin, CNRS 8104/INSERM U1016, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mélé</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, GHU Paris Psychatrie et Neurosciences, Saint Anne Hospital Centre, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM 1266 FHU NeuroVasc, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunogue</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hôpital Cochin, Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Université Paris Cité, Hôpital Cochin, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boutboul</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Hematology, Université Paris Cité, Hôpital Cochin, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farhat</LastName><ForeName>Meryem</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Université de Lille, CHU de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hachulla</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Université de Lille, CHU de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazrek</LastName><ForeName>Mouna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology, CHU de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rieu</LastName><ForeName>Virginie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathian</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7653-6528</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine 2, Centre de référence pour le Lupus, Syndrome des anti-phospholipides et autres maladies auto-immunes rares, Institut E3M, Groupe Hospitalier La Pitié Salpêtrière-Charles Foix, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM, Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaussade</LastName><ForeName>Helene</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Université de Bordeaux, CHU Bordeaux GH Pellegrin, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruet</LastName><ForeName>Aurelie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Université de Bordeaux, CHU de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burrel</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Virology, CHU de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 5234, Fundamental Microbiology and Pathogenicity, CNRS, Université de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coury-Lucas</LastName><ForeName>Fabienne</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9175-8620</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Université Claude Bernard Lyon 1, CHU Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuffenecker</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Virology, National Reference Centre for Enteroviruses and Parechoviruses, Associated Laboratory, Université Claude Bernard Lyon 1, CHU Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemaignen</LastName><ForeName>Adrien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, CHU de Tours, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefic</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Virology, CHU de Tours, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>le Besnerais</LastName><ForeName>Maelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, CHU de Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrette</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology, CHU de Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouthon</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Université Paris Cité, Hôpital Cochin, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avettand-Fenoel</LastName><ForeName>Veronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Virology, Hôpital Cochin, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Cochin, CNRS 8104/INSERM U1016, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terrier</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-6612-7336</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Université Paris Cité, Hôpital Cochin, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadjadj</LastName><ForeName>Jérome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Sorbonne Université, Hôpital Saint-Antoine, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018951" MajorTopicYN="Y">Antigens, CD20</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008590" MajorTopicYN="N">Meningoencephalitis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000361" MajorTopicYN="N">Agammaglobulinemia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B-lymphocytes</Keyword><Keyword MajorTopicYN="N">antirheumatic agents</Keyword><Keyword MajorTopicYN="N">autoimmune diseases</Keyword><Keyword MajorTopicYN="N">rituximab</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>22</Day><Hour>1</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>22</Day><Hour>1</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>21</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38772678</ArticleId><ArticleId IdType="pmc">PMC11328644</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2023-004036</ArticleId><ArticleId IdType="pii">rmdopen-2023-004036</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Harvala H, Broberg E, Benschop K, et al. Recommendations for Enterovirus diagnostics and Characterisation within and beyond Europe. J Clin Virol. 2018;101:11–7. doi: 10.1016/j.jcv.2018.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2018.01.008</ArticleId><ArticleId IdType="pubmed">29414181</ArticleId></ArticleIdList></Reference><Reference><Citation>Khetsuriani N, Lamonte A, Oberste MS, et al. Neonatal Enterovirus infections reported to the National Enterovirus surveillance system in the United States, 1983-2003. Pediatr Infect Dis J. 2006;25:889–93. doi: 10.1097/01.inf.0000237798.07462.32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000237798.07462.32</ArticleId><ArticleId IdType="pubmed">17006282</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Wang H, Tang J, et al. Clinical characteristics of severe neonatal Enterovirus infection: a systematic review. BMC Pediatr. 2021;21:127. doi: 10.1186/s12887-021-02599-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12887-021-02599-y</ArticleId><ArticleId IdType="pmc">PMC7958388</ArticleId><ArticleId IdType="pubmed">33722228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bearden D, Collett M, Quan PL, et al. Enteroviruses in X-linked Agammaglobulinemia: update on epidemiology and therapy∗. J Allergy Clin Immunol Pract. 2016;4:1059–65. doi: 10.1016/j.jaip.2015.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2015.12.015</ArticleId><ArticleId IdType="pubmed">26883540</ArticleId></ArticleIdList></Reference><Reference><Citation>Paccoud O, Mahlaoui N, Moshous D, et al. Current spectrum of infections in patients with X-linked Agammaglobulinemia. J Clin Immunol. 2021;41:1266–71. doi: 10.1007/s10875-021-01043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01043-1</ArticleId><ArticleId IdType="pubmed">33880703</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday E, Winkelstein J, Webster ADB. Enteroviral infections in primary immunodeficiency (PID): A survey of morbidity and mortality. J Infect. 2003;46:1–8. doi: 10.1053/jinf.2002.1066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jinf.2002.1066</ArticleId><ArticleId IdType="pubmed">12504601</ArticleId></ArticleIdList></Reference><Reference><Citation>Tellez R, Lastinger AM, Hogg JP. Chronic Enteroviral Meningoencephalitis in a patient on Rituximab for the treatment of Psoriatic arthritis: A case report and brief literature review. IDCases. 2019;17:e00558. doi: 10.1016/j.idcr.2019.e00558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idcr.2019.e00558</ArticleId><ArticleId IdType="pmc">PMC6522838</ArticleId><ArticleId IdType="pubmed">31193253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirand A, le Sage FV, Pereira B, et al. Ambulatory pediatric surveillance of hand, foot and mouth disease as signal of an outbreak of Coxsackievirus A6 infections, France, 2014-2015. Emerg Infect Dis . 2016;22:1884–93. doi: 10.3201/eid2211.160590.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2211.160590</ArticleId><ArticleId IdType="pmc">PMC5088007</ArticleId><ArticleId IdType="pubmed">27767012</ArticleId></ArticleIdList></Reference><Reference><Citation>Nix WA, Oberste MS, Pallansch MA. Sensitive, Seminested PCR amplification of Vp1 sequences for direct identification of all Enterovirus Serotypes from original clinical specimens. J Clin Microbiol. 2006;44:2698–704. doi: 10.1128/JCM.00542-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00542-06</ArticleId><ArticleId IdType="pmc">PMC1594621</ArticleId><ArticleId IdType="pubmed">16891480</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomba Ngangas S, Bisseux M, Jugie G, et al. Coxsackievirus A6 recombinant Subclades D3/A and D3/H were predominant in hand-foot-and-mouth disease outbreaks in the Paediatric population, France, 2010–2018. Viruses. 2022;14:1078. doi: 10.3390/v14051078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14051078</ArticleId><ArticleId IdType="pmc">PMC9144281</ArticleId><ArticleId IdType="pubmed">35632819</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailly JL, Chambon M, Peigue-Lafeuille H, et al. Activity of Glutaraldehyde at low concentrations (less than 2%) against Poliovirus and its relevance to gastrointestinal Endoscope Disinfection procedures. Appl Environ Microbiol. 1991;57:1156–60. doi: 10.1128/aem.57.4.1156-1160.1991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aem.57.4.1156-1160.1991</ArticleId><ArticleId IdType="pmc">PMC182861</ArticleId><ArticleId IdType="pubmed">1647750</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamin CS, Pérez-Hurtado E, Oliveira L, et al. Enterovirus neutralizing antibodies, monocyte toll like receptors expression and interleukin profiles are similar between non-affected and affected siblings from long-term discordant type 1 diabetes Multiplex-Sib families: the importance of HLA background. Front Endocrinol (Lausanne) 2020;11:555685. doi: 10.3389/fendo.2020.555685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.555685</ArticleId><ArticleId IdType="pmc">PMC7538605</ArticleId><ArticleId IdType="pubmed">33071971</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyet LA, Thanh TT, Nhan LNT, et al. Neutralizing antibodies against Enteroviruses in patients with hand, foot and mouth disease. Emerg Infect Dis . 2020;26:298–306. doi: 10.3201/eid2602.190721.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2602.190721</ArticleId><ArticleId IdType="pmc">PMC6986819</ArticleId><ArticleId IdType="pubmed">31961293</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheema S, Bunting E, Good C, et al. Balancing immunosuppression and infection: recurrent Enterovirus encephalitis in SLE. Pract Neurol. 2019;19:508–10. doi: 10.1136/practneurol-2019-002229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/practneurol-2019-002229</ArticleId><ArticleId IdType="pubmed">31171649</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook SG, Ford AW, Lindholm DA, et al. Enteroviral Meningoencephalitis as a complication of Rituximab therapy for rheumatoid arthritis. Cureus. 2021;13:e18189. doi: 10.7759/cureus.18189.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.18189</ArticleId><ArticleId IdType="pmc">PMC8533663</ArticleId><ArticleId IdType="pubmed">34707960</ArticleId></ArticleIdList></Reference><Reference><Citation>Diarra A, Gantois G, Lazrek M, et al. Fatal Enterovirus-related myocarditis in a patient with Devic’s syndrome treated with Rituximab. Card Fail Rev . 2021;7:e09. doi: 10.15420/cfr.2020.33.</Citation><ArticleIdList><ArticleId IdType="doi">10.15420/cfr.2020.33</ArticleId><ArticleId IdType="pmc">PMC8135016</ArticleId><ArticleId IdType="pubmed">34035954</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein S, Thakkar R, Fong KT, et al. Compassionate-use Pocapavir and immunoglobulin therapy for treatment of Rituximab-associated Enterovirus Meningoencephalitis. J Neurovirol. 2022;28:329–34. doi: 10.1007/s13365-021-01038-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-01038-z</ArticleId><ArticleId IdType="pubmed">34981437</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapadia RK, Gill CM, Baca C, et al. Enterovirus A71 causing Meningoencephalitis and acute flaccid Myelitis in a patient receiving Rituximab. J Neuroimmunol. 2021;358:S0165-5728(21)00166-1. doi: 10.1016/j.jneuroim.2021.577639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577639</ArticleId><ArticleId IdType="pubmed">34214953</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingel K, Pöml P, Strunk J, et al. Lethal Enterovirus myocarditis in a patient with granulomatosis with polyangiitis following Rituximab and high-dose steroid therapy. Eur Heart J. 2021;42:2401. doi: 10.1093/eurheartj/ehab269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab269</ArticleId><ArticleId IdType="pubmed">34021319</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy R, Mahévas M, Galicier L, et al. Profound symptomatic Hypogammaglobulinemia: A rare late complication after Rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature. Autoimmun Rev. 2014;13:1055–63. doi: 10.1016/j.autrev.2014.08.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.08.036</ArticleId><ArticleId IdType="pubmed">25183241</ArticleId></ArticleIdList></Reference><Reference><Citation>Luciani L, Ninove L, Zandotti C, et al. Fatal underhanded chronic Enterovirus infection associated with anti-Cd20 monotherapy for central nervous system Demyelinating disease. Mult Scler. 2021;27:320–3. doi: 10.1177/1352458520923978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458520923978</ArticleId><ArticleId IdType="pubmed">32584194</ArticleId></ArticleIdList></Reference><Reference><Citation>Maillet F, Pineton De Chambrun M, Monzani Q, et al. Enteroviral infections in adults treated with Rituximab: A new case of chronic meningitis and Myofasciitis and literature review. Rev Med Interne. 2020;41:200–5. doi: 10.1016/j.revmed.2019.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.revmed.2019.12.018</ArticleId><ArticleId IdType="pubmed">31980187</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios T, Bartelt L, Scheld W, et al. Fatal Coxsackie Meningoencephalitis in a patient with B-cell Lymphopenia and Hypogammaglobulinemia following Rituximab therapy. Ann Allergy Asthma Immunol. 2015;115:148–50. doi: 10.1016/j.anai.2015.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anai.2015.05.007</ArticleId><ArticleId IdType="pmc">PMC4608550</ArticleId><ArticleId IdType="pubmed">26048250</ArticleId></ArticleIdList></Reference><Reference><Citation>Quartier P, Tournilhac O, Archimbaud C, et al. Enteroviral Meningoencephalitis after Anti‐Cd20 (Rituximab) treatment. CLIN INFECT DIS. 2003;36:e47–9. doi: 10.1086/345746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/345746</ArticleId><ArticleId IdType="pubmed">12539090</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier-Leclerc A-L, Belli E, Guérin V, et al. Fulminant viral myocarditis after Rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol. 2013;28:1875–9. doi: 10.1007/s00467-013-2485-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-013-2485-9</ArticleId><ArticleId IdType="pubmed">23700173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sham L, Bitnun A, Branson H, et al. Treatment of Rituximab-associated chronic CNS Enterovirus using Ivig and fluoxetine. Neurology. 2019;92:916–8. doi: 10.1212/WNL.0000000000007468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007468</ArticleId><ArticleId IdType="pubmed">30944242</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekin B, Boire N, Shah K, et al. Viral Panniculitis in a patient with disseminated opportunistic Enterovirus infection. J Cutan Pathol. 2021;48:434–8. doi: 10.1111/cup.13930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cup.13930</ArticleId><ArticleId IdType="pubmed">33277938</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema KL, Simonson PD, Greninger AL, et al. Acute liver failure due to Echovirus 9 associated with persistent B-cell depletion from Rituximab. Open Forum Infect Dis. 2017;4:ofx174. doi: 10.1093/ofid/ofx174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofx174</ArticleId><ArticleId IdType="pmc">PMC5604094</ArticleId><ArticleId IdType="pubmed">28948184</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolini LA, Canepa P, Caligiuri P, et al. Fulminant hepatitis associated with Echovirus 25 during treatment with Ocrelizumab for multiple sclerosis. JAMA Neurol. 2019;76:866–7. doi: 10.1001/jamaneurol.2019.0522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.0522</ArticleId><ArticleId IdType="pmc">PMC6583842</ArticleId><ArticleId IdType="pubmed">30958517</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidar G, Agha M, Bilderback A, et al. Prospective evaluation of Coronavirus disease 2019 (COVID-19) vaccine responses across a broad spectrum of Immunocompromising conditions: the COVID-19 vaccination in the immunocompromised study (COVICS) Clin Infect Dis. 2022;75:e630–44. doi: 10.1093/cid/ciac103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac103</ArticleId><ArticleId IdType="pmc">PMC8903515</ArticleId><ArticleId IdType="pubmed">35179197</ArticleId></ArticleIdList></Reference><Reference><Citation>Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with Rituximab: a cohort study. Lancet Rheumatol . 2021;3:e419–26. doi: 10.1016/S2665-9913(21)00059-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00059-X</ArticleId><ArticleId IdType="pmc">PMC7993930</ArticleId><ArticleId IdType="pubmed">33786454</ArticleId></ArticleIdList></Reference><Reference><Citation>CNR enterovirus. Clermont-Ferrand-Lyon: France  French Reference Centre for enteroviruses and parechovirus. http://cnr.chu-clermontferrand.fr/CNR Available.</Citation></Reference><Reference><Citation>Bauer L, Manganaro R, Zonsics B, et al. Fluoxetine inhibits Enterovirus replication by targeting the viral 2C protein in a Stereospecific manner. ACS Infect Dis. 2019;5:1609–23. doi: 10.1021/acsinfecdis.9b00179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.9b00179</ArticleId><ArticleId IdType="pmc">PMC6747591</ArticleId><ArticleId IdType="pubmed">31305993</ArticleId></ArticleIdList></Reference><Reference><Citation>Bearden D, Collett M, Quan PL, et al. Enteroviruses in X-linked Agammaglobulinemia: update on epidemiology and therapy. J Allergy Clin Immunol Pract. 2016;4:1059–65. doi: 10.1016/j.jaip.2015.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2015.12.015</ArticleId><ArticleId IdType="pubmed">26883540</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>